市場調査レポート
商品コード
1226564
CAEL-101:新興治療薬の分析・市場予測 (~2032年)CAEL-101 Emerging Drug Insight and Market Forecast - 2032 |
● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。 詳細はお問い合わせください。
CAEL-101:新興治療薬の分析・市場予測 (~2032年) |
出版日: 受注後更新
発行: DelveInsight
ページ情報: 英文 30 Pages
納期: 2~10営業日
|
当レポートでは、世界の主要7カ国 (米国・ドイツ・フランス・イタリア・スペイン・英国・日本) におけるALアミロイドーシス治療薬CAEL-101の動向を調査し、当該薬剤の作用機序、規制上のマイルストーン、臨床試験の動向、開発後期の新興治療薬の概要、市場規模の推移・予測、国別の詳細分析、特許動向、アナリストの見解などをまとめています。
"CAEL-101 Emerging Drug Insight and Market Forecast - 2032" report provides comprehensive insights about CAEL-101 for AL Amyloidosis in the 7MM. A detailed picture of the CAEL-101 for AL Amyloidosis in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019-2032 is provided in this report along with a detailed description of the CAEL-101 for AL Amyloidosis. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the CAEL-101 market forecast, analysis for AL Amyloidosis in the 7MM, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about emerging therapies in AL Amyloidosis.
CAEL-101 (previously known as 11-1F4) is a first-in-class, light chain fibril-reactive mAb (monoclonal antibody) being developed as targeted therapy by Caelum Biosciences. The therapy is designed to improve organ function by reducing or eliminating amyloid deposits in the tissues and organs of patients with AL amyloidosis. The antibody has a unique capability of binding to misfolded light chain proteins, especially to both kappa and lambda subtypes of amyloid proteins.
CAEL-101 has received Orphan Drug Designation from both the FDA and EMA as a therapy for patients with AL amyloidosis.
The company initiated Phase III clinical studies to treat AL amyloidosis patients. The Cardiac Amyloid Reaching for Extended Survival (CARES) clinical program includes two parallel Phase III studies-one in patients with Mayo stage IIIa disease and another in patients with Mayo stage IIIb disease. They will collectively enroll approximately 370 patients globally.
The report provides insights into:
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
CAEL-101 Analytical Perspective by DelveInsight
This report provides a detailed market assessment of CAEL-101 in AL Amyloidosis in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2023 to 2032.
The report provides the clinical trials information of CAEL-101 for AL Amyloidosis covering trial interventions, trial conditions, trial status, start and completion dates.
Key Questions